Characteristics and related factors of lipid profiles in ankylosing spondylitis_West China Medical Journal

Authors：

 GENG Yao ¹ , WANG Han ² , YIN Zhiliang ¹ , ZHU Xianzhong ¹

1. Department of Orthopedics, Chengfei Hospital, Chengdu, Sichuan 610091, P. R. China;
2. Departemnt of Cardiology, the No. 3 People’s Hospital of Chengdu, Chengdu, Sichuan 610031, P. R. China;

Corresponding?author：

GENG Yao, Email: 2236694489@qq.com

Keywords：

Ankylosing spondylitis; Triacylglycerol; High-density lipoprotein cholesterol; C-reactive protein

DOI：

10.7507/1002-0179.201610108

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the characteristics and the related factors of the lipid profiles in patients with ankylosing spondylitis (AS). Methods Sixty AS patients and 60 healthy controls were included retrospectively from January 2005 to January 2015. Information including general data, physical examination, and blood sample were collected; triacylglycerol (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), high-density lipoprotein cholesterol (HDL-C), and C-reactive protein (CRP) were assessed. Results TG increased in 46.7% (28/60) patients, and HDL-C decreased in 50.0% (30/60). Compared with the control group, AS patients had lower levels of HDL-C, TC and LDL-C, and higher levels of TG, VLDL-C, VLDL-C/LDL-C ratio, LDL-C/HDL-C ratio, and TC/HDL-C ratio; the differences above were all statistically significant (P<0.01). Spearman correlation test demonstrated that HDL-C level was correlated negatively with serum CRP (r_s=–0.359, P=0.005). Multiple linear regression model demonstrated that CRP was associated with HDL-C in AS patients (P=0.019). Conclusions Dyslipoproteinemia is a common feature in AS patients. The main characteristic is the increase of TG and decrease of HDL-C, related with inflammation. It suggests a high risk of atherosclerosis.

Citation： GENG Yao, WANG Han, YIN Zhiliang, ZHU Xianzhong. Characteristics and related factors of lipid profiles in ankylosing spondylitis. West China Medical Journal, 2017, 32(9): 1379-1382. doi: 10.7507/1002-0179.201610108 Copy

1.	鄧蓉, 梁燕, 譚小波, 等. 強直性脊柱炎患者自我管理狀況調查分析. 華西醫學, 2015, 30(1): 115-118.
2.	Semb AG, Kvien TK, Demicco DA, et al. Prediction of cardiovascular events in patients with ankylosing spondylitis and psoriatic arthritis: role of lipoproteins in a high-risk population. J Rheumatol, 2012, 39(7): 1433-1440.
3.	Atzeni F, Corda M, Sarzi-Puttini P, et al. From old to new cardiovascular complications in ankylosing spondylitis. Isr Med Assoc J, 2017, 19(8): 506-509.
4.	Mathieu S, Gossec L, Dougados M, et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken), 2011, 63(4): 557-563.
5.	Lin FJ, Tseng WK, Yin WH, et al. Residual risk factors to predict major adverse cardiovascular events in atherosclerotic cardiovascular disease patients with and without diabetes mellitus. Sci Rep, 2017, 7(1): 9179.
6.	Raychaudhuri SP, Deodhar A. The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun, 2014, 48-49(1): 128-133.
7.	Wang G, Pierangeli SS, Willis R, et al. Significance of lipid-derived reactive aldehyde-specific immune complexes in systemic lupus erythematosus. PLoS One, 2016, 11(10): e0164739.
8.	Djokovi? A, Stojanovi? L. Cardiac manifestations in antiphospholipid syndrome. A brief review of the literature. Srp Arh Celok Lek, 2015, 143(5/6): 346-353.
9.	中華醫學會心血管病學分會, 中國老年學學會心腦血管病專業委員會. 血脂相關性心血管剩余風險控制的中國專家共識. 中華心血管病雜志, 2011, 40(1): 547-553.
10.	Machado D, Sarni RO, Abad TT, et al. Lipid profile among girls with systemic lupus erythematosus. Rheumatol Int, 2017, 37(1): 43-48.
11.	Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum, 2009, 38(5): 372-381.
12.	吳智鴻, 趙水平. 類風濕關節炎與冠心病. 中華風濕病學雜,2004, 8(11): 688-690.
13.	Yeh ET. CRP as a mediator of disease. Circulation, 2004, 109(21, S): 11-14.
14.	Asanuma Y, Chung CP, Oeser A, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol, 2006, 33(3): 539-545.
15.	Heslinga SC, Peters MJ, Ter Wee MM, et al. Reduction of inflammation drives lipid changes in ankylosing spondylitis. J Rheumatol, 2015, 42(10): 1842-1845.
16.	Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum, 2012, 64(1): 285-296.
17.	Mathieu S, Dubost JJ, Tournadre A, et al. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine, 2010, 77(1): 50-52.

1. 鄧蓉, 梁燕, 譚小波, 等. 強直性脊柱炎患者自我管理狀況調查分析. 華西醫學, 2015, 30(1): 115-118.
2. Semb AG, Kvien TK, Demicco DA, et al. Prediction of cardiovascular events in patients with ankylosing spondylitis and psoriatic arthritis: role of lipoproteins in a high-risk population. J Rheumatol, 2012, 39(7): 1433-1440.
3. Atzeni F, Corda M, Sarzi-Puttini P, et al. From old to new cardiovascular complications in ankylosing spondylitis. Isr Med Assoc J, 2017, 19(8): 506-509.
4. Mathieu S, Gossec L, Dougados M, et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken), 2011, 63(4): 557-563.
5. Lin FJ, Tseng WK, Yin WH, et al. Residual risk factors to predict major adverse cardiovascular events in atherosclerotic cardiovascular disease patients with and without diabetes mellitus. Sci Rep, 2017, 7(1): 9179.
6. Raychaudhuri SP, Deodhar A. The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun, 2014, 48-49(1): 128-133.
7. Wang G, Pierangeli SS, Willis R, et al. Significance of lipid-derived reactive aldehyde-specific immune complexes in systemic lupus erythematosus. PLoS One, 2016, 11(10): e0164739.
8. Djokovi? A, Stojanovi? L. Cardiac manifestations in antiphospholipid syndrome. A brief review of the literature. Srp Arh Celok Lek, 2015, 143(5/6): 346-353.
9. 中華醫學會心血管病學分會, 中國老年學學會心腦血管病專業委員會. 血脂相關性心血管剩余風險控制的中國專家共識. 中華心血管病雜志, 2011, 40(1): 547-553.
10. Machado D, Sarni RO, Abad TT, et al. Lipid profile among girls with systemic lupus erythematosus. Rheumatol Int, 2017, 37(1): 43-48.
11. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum, 2009, 38(5): 372-381.
12. 吳智鴻, 趙水平. 類風濕關節炎與冠心病. 中華風濕病學雜,2004, 8(11): 688-690.
13. Yeh ET. CRP as a mediator of disease. Circulation, 2004, 109(21, S): 11-14.
14. Asanuma Y, Chung CP, Oeser A, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol, 2006, 33(3): 539-545.
15. Heslinga SC, Peters MJ, Ter Wee MM, et al. Reduction of inflammation drives lipid changes in ankylosing spondylitis. J Rheumatol, 2015, 42(10): 1842-1845.
16. Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum, 2012, 64(1): 285-296.
17. Mathieu S, Dubost JJ, Tournadre A, et al. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine, 2010, 77(1): 50-52.

West China Medical Journal

Characteristics and related factors of lipid profiles in ankylosing spondylitis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content